Arcus Biosciences, Inc. (RCUS)

NYSE: RCUS · IEX Real-Time Price · USD
17.65
+0.03 (0.17%)
Mar 27, 2023, 4:00 PM EDT - Market closed

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019201820172016
Revenue
11238378158.351.410
Revenue Growth (YoY)
-70.76%391.03%420.00%79.58%491.15%--
Gross Profit
11238378158.351.410
Selling, General & Admin
104724325.2313.577.643.94
Research & Development
28825715978.4849.6547.2214.25
Operating Expenses
392329202103.7163.2154.8518.18
Operating Income
-28054-124-88.71-54.86-53.44-18.18
Interest Expense / Income
00000-0.78-0.21
Other Expense / Income
-14-1-1-4-5.270.42-
Pretax Income
-26655-123-84.71-49.59-53.08-17.97
Income Tax
1200000
Net Income
-26753-123-84.71-49.59-53.08-17.97
Shares Outstanding (Basic)
726955443521
Shares Outstanding (Diluted)
727455443521
Shares Change
-2.70%35.04%25.04%26.60%1793.51%111.61%-
EPS (Basic)
-3.710.76-2.24-1.93-1.43-29.03-20.80
EPS (Diluted)
-3.710.71-2.24-1.93-1.43-29.03-20.80
Free Cash Flow Per Share
6.00-4.071.97-1.72-1.35-16.72-19.73
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-250.00%14.10%-158.97%-591.39%-656.76%-3782.09%-
Profit Margin
-238.39%13.84%-157.69%-564.73%-593.73%-3756.69%-
Free Cash Flow Margin
385.71%-73.63%138.46%-502.58%-559.55%-2163.69%-
Effective Tax Rate
-3.64%-----
EBITDA
-25262-119-81.13-45.93-51.25-16.87
EBITDA Margin
-225.00%16.19%-152.56%-540.88%-549.86%-3626.68%-
Depreciation & Amortization
14743.583.662.611.31
EBIT
-26655-123-84.71-49.59-53.86-18.18
EBIT Margin
-237.50%14.36%-157.69%-564.73%-593.73%-3811.54%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).